Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?

Psilocybin, a drug most commonly recognized as a recreational psychedelic, is quickly gaining attention as a promising therapy for an expanding range of neurological conditions, including depression, anxiety, and addiction. This growing interest has led to many recent advancements in psilocybin synt...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	William J. Gibbons, Madeline G. McKinney, Philip J. O’Dell, Brooke A. Bollinger, J. Andrew Jones
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	psilocybin regulation homebrewed drugs recombinant dna technology Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/d8bd116372e74aefb9a4cdaa8d2ccdf3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d8bd116372e74aefb9a4cdaa8d2ccdf3
record_format	dspace
spelling	oai:doaj.org-article:d8bd116372e74aefb9a4cdaa8d2ccdf32021-11-04T15:51:53ZHomebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?2165-59792165-598710.1080/21655979.2021.1987090https://doaj.org/article/d8bd116372e74aefb9a4cdaa8d2ccdf32021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/21655979.2021.1987090https://doaj.org/toc/2165-5979https://doaj.org/toc/2165-5987Psilocybin, a drug most commonly recognized as a recreational psychedelic, is quickly gaining attention as a promising therapy for an expanding range of neurological conditions, including depression, anxiety, and addiction. This growing interest has led to many recent advancements in psilocybin synthesis strategies, including multiple in vivo fermentation-based approaches catalyzed by recombinant microorganisms. In this work, we show that psilocybin can be produced in biologically relevant quantities using a recombinant E. coli strain in a homebrew style environment. In less than 2 days, we successfully produced approximately 300 mg/L of psilocybin under simple conditions with easily sourced equipment and supplies. This finding raises the question of how this new technology should be regulated as to not facilitate clandestine biosynthesis efforts, while still enabling advancements in psilocybin synthesis technology for pharmaceutical applications. Here, we present our homebrew results, and suggestions on how to address the regulatory concerns accompanying this new technology.William J. GibbonsMadeline G. McKinneyPhilip J. O’DellBrooke A. BollingerJ. Andrew JonesTaylor & Francis Grouparticlepsilocybinregulationhomebrewed drugsrecombinant dna technologyBiotechnologyTP248.13-248.65ENBioengineered, Vol 12, Iss 1, Pp 8863-8871 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	psilocybin regulation homebrewed drugs recombinant dna technology Biotechnology TP248.13-248.65
spellingShingle	psilocybin regulation homebrewed drugs recombinant dna technology Biotechnology TP248.13-248.65 William J. Gibbons Madeline G. McKinney Philip J. O’Dell Brooke A. Bollinger J. Andrew Jones Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?
description	Psilocybin, a drug most commonly recognized as a recreational psychedelic, is quickly gaining attention as a promising therapy for an expanding range of neurological conditions, including depression, anxiety, and addiction. This growing interest has led to many recent advancements in psilocybin synthesis strategies, including multiple in vivo fermentation-based approaches catalyzed by recombinant microorganisms. In this work, we show that psilocybin can be produced in biologically relevant quantities using a recombinant E. coli strain in a homebrew style environment. In less than 2 days, we successfully produced approximately 300 mg/L of psilocybin under simple conditions with easily sourced equipment and supplies. This finding raises the question of how this new technology should be regulated as to not facilitate clandestine biosynthesis efforts, while still enabling advancements in psilocybin synthesis technology for pharmaceutical applications. Here, we present our homebrew results, and suggestions on how to address the regulatory concerns accompanying this new technology.
format	article
author	William J. Gibbons Madeline G. McKinney Philip J. O’Dell Brooke A. Bollinger J. Andrew Jones
author_facet	William J. Gibbons Madeline G. McKinney Philip J. O’Dell Brooke A. Bollinger J. Andrew Jones
author_sort	William J. Gibbons
title	Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?
title_short	Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?
title_full	Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?
title_fullStr	Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?
title_full_unstemmed	Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?
title_sort	homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/d8bd116372e74aefb9a4cdaa8d2ccdf3
work_keys_str_mv	AT williamjgibbons homebrewedpsilocybincannewroutesforpharmaceuticalpsilocybinproductionenablerecreationaluse AT madelinegmckinney homebrewedpsilocybincannewroutesforpharmaceuticalpsilocybinproductionenablerecreationaluse AT philipjodell homebrewedpsilocybincannewroutesforpharmaceuticalpsilocybinproductionenablerecreationaluse AT brookeabollinger homebrewedpsilocybincannewroutesforpharmaceuticalpsilocybinproductionenablerecreationaluse AT jandrewjones homebrewedpsilocybincannewroutesforpharmaceuticalpsilocybinproductionenablerecreationaluse
_version_	1718444743783874560

Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?

Ejemplares similares